Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rizatriptan ODT for Migraine-Associated Nausea
NCT00250458Phase 3
Key facts
- Status
- Completed
- Start
- Mar 2006
- Primary completion
- Oct 2006
- Sponsor
- Organon & Co.
- Modality
- Small Molecules
- Drugs
- rizatriptan
- Conditions
- migraine
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Rizatriptan with Placebo (2 arms). Primary endpoint: Participants With Elimination of Nausea at 2 Hours Postdose. Started Mar 2006; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Rizatriptan
Rizatriptan 10 mg ODT
Placebo
Matching Placebo
03
Who it enrols
Patients with a 6-month history of migraine experiencing 1-6 moderate to severe attacks with nausea per month. Patients with heart disease or high blood pressure are excluded.
04
Endpoints
Primary
Participants With Elimination of Nausea at 2 Hours Postdose
Secondary
Participants With Pain Relief at 2 Hours Postdose
Beyond the preview
Go deeper on NCT00250458.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250458.